Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clozapine.

M W Jann1

  • 1Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30312.

Pharmacotherapy
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Clozapine, an atypical neuroleptic, effectively treats refractory schizophrenia with fewer movement side effects than typical antipsychotics. Its unique receptor binding and metabolism offer a significant advancement in mental illness treatment, despite risks like agranulocytosis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of thioridazine on gap junction intercellular communication in connexin 43-expressing cells.

Cell biology and toxicology·2006
Same author

Repeated ingestion of grapefruit juice does not alter clozapine's steady-state plasma levels, effectiveness, and tolerability.

The Journal of clinical psychiatry·2002
Same author

Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo.

Drug metabolism and drug interactions·2002
Same author

Differences in haloperidol epidemiologic pharmacokinetic studies.

Journal of clinical psychopharmacology·2002
Same author

Seville (sour) orange juice: synephrine content and cardiovascular effects in normotensive adults.

Journal of clinical pharmacology·2001
Same author

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

CNS drugs·2001

Area of Science:

  • Pharmacology
  • Neuroscience
  • Psychiatry

Background:

  • Clozapine is an atypical neuroleptic agent, a dibenzodiazepine derivative with a piperazinyl side chain.
  • It exhibits a unique neuropharmacologic profile, differing from typical neuroleptics.
  • Its actions are specific to the cortical-limbic dopamine A-10 tract.

Purpose of the Study:

  • To detail the neuropharmacologic profile, pharmacokinetics, and clinical efficacy of clozapine.
  • To compare clozapine's efficacy and side effect profile against traditional neuroleptics, particularly chlorpromazine.
  • To highlight clozapine's role in treating refractory schizophrenia and movement disorders.

Main Methods:

  • Analysis of clozapine's binding affinities for dopamine (D-1, D-2) and serotonin (5-HT1A, 5-HT2) receptors.

Related Experiment Videos

  • Electrophysiologic studies to determine its tract specificity.
  • Review of pharmacokinetic data (absorption, half-life, metabolism) and clinical trial results (short-term, long-term, multicenter).

    • Main Results:

    • Clozapine shows weak binding to dopamine D-1 and D-2 receptors (D-1:D-2 ratio 1.3) and potent binding to 5-HT1A and 5-HT2 receptors.
    • It lacks catalepsy-inducing effects and has transient effects on dopamine agonists compared to typical neuroleptics.
    • Clozapine demonstrated superiority over chlorpromazine in treating refractory schizophrenia with minimal extrapyramidal side effects; agranulocytosis is a major concern.

    Conclusions:

    • Clozapine is a highly effective neuroleptic for refractory schizophrenia, offering a better side effect profile regarding movement disorders.
    • Its distinct receptor interactions and pharmacokinetic properties contribute to its efficacy.
    • Despite the risk of agranulocytosis, clozapine represents a significant advancement in managing severe mental illnesses.